Home › Acute Biphenotypic Leukemia › Oklahoma

Pag-aaral pangklinika para sa Acute Biphenotypic Leukemia sa Oklahoma

5 pag-aaral para sa Acute Biphenotypic Leukemia ang naghahanap ng mga kalahok sa mga site sa Oklahoma.

Mga Lungsod sa Oklahoma

Opisyal na teksto ng pag-aaral (English)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

University of Oklahoma Health Sciences Center, Oklahoma City

Nagre-recruitPhase 2

365 Days · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

University of Oklahoma Health Sciences Center, Oklahoma City
Saint Francis Children's Hospital, Tulsa

Nagre-recruitPhase 3

365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

University of Oklahoma Health Sciences Center, Oklahoma City

Nagre-recruitPhase 1/2

Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Saint Francis Children's Hospital, Tulsa

Nagre-recruitPhase 2

Edad 1 hanggang 18 · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06390319

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Saint Francis Children's Hospital, Tulsa

Nagre-recruitPhase 4

Edad 1 hanggang 18 · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT06289673

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.